On September 1, 2026, the U.S. Food and Drug Administration (FDA) issued an early alert regarding a potentially high-risk device issue involving the Draeger VentStar Resus Neo breathing circuit, a disposable medical device used to convey breathing gas to infants weighing up to 22 pounds. Draeger has notified affected customers to inspect and remove compromised hoses from where they are used or sold due to risks of cracking, detachment, and patient hypoxia.
Understanding the VentStar Resus Neo Device Defect and Clinical Risks
The FDA Center for Devices and Radiological Health (CDRH) released the early notification to warn healthcare providers about potential structural failures in the VentStar Resus Neo breathing circuit. According to official regulatory filings, Draeger initiated customer communications after identifying instances where obvious physical cracks formed in the device hose before clinical deployment.
When a compromised breathing circuit is used in critical and emergency situations, the mechanical stress of ventilation can cause the damaged hose to completely detach or leak air. This structural failure leads directly to restricted ventilation or delayed therapeutic delivery. Such interruptions can precipitate acute clinical deterioration, including desaturation and hypoxia, which carries a risk of patient mortality.
As of August 27, 2026, Draeger reported zero serious injuries or patient deaths associated with this hardware defect.
In Plain English: The Clinical Takeaway
- The Device Involved: The Draeger VentStar Resus Neo, a single-use breathing tube system designed to deliver oxygen and respiratory gases to infants under 22 pounds.
- The Core Hazard: Certain hoses can develop visible cracks or detach entirely, which cuts off or reduces the flow of vital air to a newborn.
- Required Action: Clinicians must inspect all inventory immediately. Any cracked or detached hose must be discarded right away without waiting to return the hardware to the manufacturer.
Regulatory Response and Institutional Guidance Across Healthcare Systems
The FDA and CDRH are actively reviewing incoming safety data and plan to update public health channels as further details emerge. Unlike formal product recalls that mandate physical return logistics, Draeger’s current advisory instructs facilities to manage inventory directly at the point of care by segregating and discarding defective units.
The UDI system enables hospitals and regulatory bodies to analyze adverse event reporting with high granularity, isolating affected production lots swiftly. Healthcare professionals and hospital risk officers observing any quality anomalies or device failures are urged to submit structured incident reports through MedWatch, the FDA Safety Information and Adverse Event Reporting Program.
| Parameter | Clinical Detail |
|---|---|
| Affected Device | Draeger VentStar Resus Neo (Disposable Breathing Circuit) |
| Patient Population | Infants weighing up to 22 lbs |
| Identified Defect | Hose cracking and potential physical detachment |
| Primary Clinical Risk | Restricted ventilation, air leakage, desaturation, and hypoxia |
| Reported Casualties | Zero serious injuries or deaths reported as of August 27, 2026 |
| Manufacturer Contact | 445-224-0698 or [email protected] |
Contraindications & When to Consult a Doctor
Clinicians with clinical questions or those seeking clarification on affected serial numbers should contact Draeger directly at 445-224-0698 or via email at [email protected]. Adverse events experienced with these devices should be documented and transmitted to the FDA MedWatch portal.
References
- U.S. Food and Drug Administration (FDA). Early Alert: Breathing Circuit Issue from Draeger. Medical Device Recalls and Early Alerts.
- U.S. Food and Drug Administration. Early Alert: Breathing Circuit Issue from Draeger (GovDelivery Bulletin).
